Surgical simulation steps into a new phase in ophthalmology

Tern plc

In the niche but technically demanding world of ophthalmology, a new approach to training is gaining ground. The traditional reliance on live surgical observation and supervised repetition is being supplemented, and in some cases, pre-empted, by immersive extended reality. At the centre of this evolution is a structured rollout model that reframes simulation as a progressive system of implementation.

Fundamental XR has laid out a clear, phased framework for XR adoption, beginning with pilot testing and moving deliberately through infrastructure deployment, staff onboarding, content calibration, and outcome tracking. This matters because while extended reality has been circulating in healthcare discussions for years, what has often been missing is a replicable model for institutional uptake, something that works beyond a showcase or demo setting.

What makes this opportunity distinctive is that it bypasses much of the hype surrounding general-use XR platforms. Instead, it targets a clear pain point, surgical training bottlenecks, with a solution that is already seeing traction across professional institutions.

Developing and maintaining specialty-specific content, adapting to new surgical techniques and staying aligned with evolving training standards all require sustained investment. But these same factors create defensible barriers to entry. In fields like ophthalmology, where each device or procedure has unique requirements, the demand for high-fidelity simulation remains acute, and unlikely to be met by generalist solutions.

More importantly, this model may not stay confined to one field. If the implementation roadmap proves successful in ophthalmology, there is a clear logic to extending it into other surgical specialities.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Talking Medicines targets a growing data need around GLP-1 treatment journeys

Talking Medicines is using GLP-1 discontinuation conversations to show how DrugVoice can help pharmaceutical companies track changing patient needs across the treatment journey.

Device Authority adopts usage-based pricing to support KeyScaler expansion

Device Authority has moved KeyScaler to usage-based pricing, aiming to reduce licensing friction and support broader adoption of its machine identity security platform.

Talking Medicines targets growing demand for GLP-1 patient intelligence

Talking Medicines is using GLP-1 patient conversations to show how behavioural data can help pharmaceutical companies understand changing treatment expectations and engagement.

Talking Medicines builds its AI strategy around specialist life sciences intelligence

Talking Medicines is positioning specialist healthcare intelligence as the core layer that gives agentic AI useful context in life sciences.

Device Authority targets cyber resilience opportunity at TechWorks Summit 2026

Device Authority will focus on continuous IoT and OT compliance, AI and quantum risk at TechWorks Summit 2026 as it strengthens its position in connected-device security.

Talking Medicines builds a more defensible AI model for life sciences

Talking Medicines is combining proprietary healthcare intelligence, AI agents and orchestration to build a more specialised AI platform for life sciences.

Search